Annovation BioPharma is a technology company.
Annovation BioPharma has raised $10.0M across 2 funding rounds.
Annovation BioPharma has raised $10.0M in total across 2 funding rounds.
Annovation BioPharma has raised $10.0M in total across 2 funding rounds.
Annovation BioPharma's investors include Atlas Venture.
Annovation BioPharma was a biopharmaceutical company developing novel intravenous anesthetics for anesthesia, sedation, and critical care, with its lead candidate ABP-700, an investigational rapidly acting IV anesthetic licensed from Massachusetts General Hospital.[1][2][5] It targeted surgical and procedural care, aiming to provide more effective, safer therapies with potent and rapidly reversible effects, addressing unmet needs in an area with few advances in 30 years amid ~230 million annual global surgical procedures.[1][4] The company served hospitals and perioperative care settings, solving problems of precise anesthesia control to improve patient outcomes and care efficiency; it reached Phase 1 clinical trials before being fully acquired by The Medicines Company in February 2015, ending its independent operations.[1][4]
Founded in 2009, Annovation BioPharma emerged from technology licensed from Massachusetts General Hospital to create advanced anesthesia agents.[1][2][3][5] Led by CEO David Grayzel, MD, who was also a Partner at Atlas Venture, the company quickly advanced ABP-700 through Phase 1 studies within less than three years, demonstrating its rapid anesthetic effects.[1] Early traction included ongoing clinical expansions and planned trials, with data presentations anticipated, before the pivotal 2015 acquisition by The Medicines Company handed over the full portfolio.[1][4]
Annovation rode the trend of targeted biopharma innovation in anesthesia and critical care, where demand for efficient, reversible agents aligned with rising global surgical volumes (~230 million procedures yearly).[1][4] Timing mattered as it filled a 30-year innovation gap, leveraging hospital-licensed tech amid growing focus on perioperative solutions by majors like The Medicines Company, which targeted acute care hospitals worldwide.[1][4] Its acquisition amplified ecosystem influence, transferring ABP-700 into a larger platform to potentially transform procedural efficiency and patient safety in surgery-heavy markets.[1]
Post-2015 acquisition, Annovation's assets like ABP-700 integrated into The Medicines Company's pipeline, likely advancing through further trials under bigger resources—though independent growth ended.[1][4] Biotech trends in precision anesthesia and critical care will shape any legacy impact, with market forces favoring rapid-onset agents for high-volume procedures. Its story underscores how nimble startups catalyze big-pharma progress, tying back to its core mission of safer, tailored anesthesia innovation.
Annovation BioPharma has raised $10.0M across 2 funding rounds. Most recently, it raised $8.0M Series A in September 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2012 | $8.0M Series A | Atlas Venture | |
| Jul 1, 2012 | $2.0M Venture Round | Atlas Venture |